4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $27.00 by Analysts at Leerink Partners

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) had its price objective decreased by equities researchers at Leerink Partners from $31.00 to $27.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Leerink Partners' price target suggests a potential upside of 467.23% from the stock's previous close.

Several other brokerages have also issued reports on FDMT. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Bank of America cut their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. Finally, Chardan Capital reiterated a "buy" rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $38.56.

4D Molecular Therapeutics Stock Down 13.8 %

Shares of NASDAQ:FDMT traded down $0.76 during mid-day trading on Monday, reaching $4.76. 1,368,492 shares of the stock were exchanged, compared to its average volume of 828,870. The company has a market cap of $220.05 million, a P/E ratio of -1.67 and a beta of 2.81. The stock's 50 day simple moving average is $7.00 and its 200-day simple moving average is $11.99. 4D Molecular Therapeutics has a one year low of $4.68 and a one year high of $36.25.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the third quarter valued at about $40,000. Values First Advisors Inc. bought a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $57,000. Quest Partners LLC grew its position in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company's stock worth $121,000 after purchasing an additional 5,745 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after purchasing an additional 3,922 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $108,000. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.